The role of viscosupplementation in patellar chondropathy

Sergio Ricardo da Costa, Roberto Freire da Mota e Albuquerque, Camilo Partezani Helito and Gilberto Luis Camanho

Abstract: Patellar chondropathy has a high incidence in the general population, being more common in patients younger than 50 years, female and recreational athletes, and overweight and obese patients. The most common complaints are pain, limited mobility, crepitus, difficulty climbing and descending stairs, and joint instability, usually showing unsatisfactory results with anti-inflammatory, physiotherapy, rehabilitation, and many other conservative treatment methods. The presumed hyaluronic acid (HA) disease-modifying activity may include effects on cartilage degradation, endogenous HA synthesis, synoviocyte and chondrocyte function, and other cellular inflammatory processes. Currently, HA is widely used as a safe and effective conservative treatment for osteoarthritis in the knee and other joints. HA improves the physiological environment in an osteoarthritic joint and the shock absorption and lubrication properties of the osteoarthritic synovial fluid, thus restoring the protective viscoelasticity of the synovial HA, reducing the pain, and improving the mobility. The complete mechanism of HA in the joint is not fully understood, but a wide range of actions in the joint is recognized. Its anti-inflammatory, analgesic, and chondroprotective action is related to the modulation of the intra- and extracellular inflammation cascade. HA has been shown to be safe and effective in the treatment of pain related to patellar chondropathy.

Keywords: knee/aetiology, knee joint/physiopathology, osteoarthritis, patellofemoral pain syndrome/physiopathology, viscosupplementation

Introduction
This narrative review will provide an overview for clinicians of recent advances in knowledge on the use of hyaluronic acid (HA) and patellar chondropathy, taking into account the causes of femoral patellar pain and the mechanism of action of HA in the joint.

Patellar chondropathy has a high incidence in the general population (1.5–7.3%) in the United States, being more common in patients younger than 50 years, in female athletes (13–17%), recreational athletes, and overweight and obese patients. The most common complaints are pain, limited mobility, crepitus, difficulty climbing and descending stairs, and joint instability, usually showing unsatisfactory results with anti-inflammatory, physiotherapy, rehabilitation, and many other conservative treatment methods.

Historically, the terms “internal derangement” of the knee and “chondromalacia patellae” have been used almost synonymously as a cause of anterior knee pain. Konrad Büdinger was the first to associate chondral fissures with traumatic knee injuries in 1906.1

The term “patellar chondropathy” refers to degenerative changes in the articular cartilage of the patella that often cause symptoms such as pain, crepitus, and joint effusion. Patellofemoral arthritis refers to degenerative changes and a significant cartilage loss in the articular surface of the patella and in the femoral trochlea. According to the scientific literature, chondropathy may progress to patellofemoral or tibiofemoral osteoarthritis, requiring a precise diagnosis, an appropriate treatment, and an accurate follow-up as preventive measures.5
The aetiology of patellofemoral pain is quite diverse: the patellar cartilage, subchondral bone, synovial plicae, anterior joint capsule, infrapatellar fat pad, and tendons certainly have their role in this process. The participation of the extensor mechanism is important since we have seen patients with pain and intact cartilage, as well as anatomic and mechanical changes: Q angle, patellar instability, shape, positioning, and patellar contact area.6

The hyaline cartilage is completely aneural, so surface defects are not believed to produce pain. Dye et al.7 published an article explaining the conscious perception of intraarticular (IA) pain through the palpation of its structures when researching the origin of patellofemoral pain. The synovium, infrapatellar fat pad, and anterior joint capsule were highly susceptible to pain, but the patellar cartilage palpation did not cause any painful sensation. This study reinforces the idea that pressure under the subchondral bone plays a role in the genesis of anterior knee pain.

Recently, Sanchis-Alfonso et al.8 observed the presence of neural growth factor (NGF) and substance P in the lateral retinaculum of patients with isolated symptomatic patellofemoral malalignment. NGF is a neurotrophin that is released during axonogenesis and inflammation and stimulates neural sprouting. It is involved in pain mechanisms by stimulating the release of neuroceptive mediators and attracting lymph cells and mastocytes, potentially releasing more cytokines, including NGF, perpetuating the cycle.

The envelope theory proposed by Dye suggests a relationship between the load (force) supported by the patellofemoral joint and the frequency of such load. Setting up zones of physiological functioning: the zone of homeostasis is within the physiological load and frequency parameters sustained by the joint for long periods without causing structural damage; when the force or frequency is excessive, the zone of structural failure of the cartilage is reached.9 Currently, studies with 3-T MRI demonstrate bone oedema and cartilage injuries within the context of repetitive trauma sports, such as long-distance running, football, and basketball, partially corroborating this theory.10,11

Viscosupplementation

HA came into clinical use in Japan and Italy 1987, in Canada in 1992, in Europe in 1995, and in the United States in 1997. Dr Endre Balaz proposed the concept of viscosupplementation in 1974 as an attempt to recover the characteristics of the synovial fluid altered in osteoarthritis (OA).12

Currently, HA is widely used as a safe and effective conservative treatment for OA13 in the knee and other joints. HA improves the physiological environment in an osteoarthritic joint and the shock absorption and lubrication properties of the osteoarthritic synovial fluid, thus restoring the protective viscoelasticity of the synovial HA, reducing the pain and improving mobility.14 According to the Osteoarthritis Research Society International classification,15 HA currently is a recommended conservative treatment for all OA degrees and has been used safely and widely around the world and in other joints (hip, shoulder, and ankle).

HA is a polysaccharide that consists of a long chain of disaccharides (β-D-glucuronyl-β-D-N-acetylglucosamine). It is a natural component of the cartilage and other tissues and plays an essential role in the viscoelastic properties of the synovial fluid. Its biological functions include maintaining the elastoviscosity of connective tissues, such as the joint synovial fluid and ocular vitreous, and controlling the tissue hydration and water transport. HA is highly hygroscopic, which is important to modulate the tissue hydration and the osmotic balance. In addition to its function as a passive structural molecule, HA also acts as a signalling molecule, interacting with cell surface receptors and regulating cell proliferation, migration, and differentiation, as well as numerous receptor-mediated roles in cell detachment, mitosis, migration, and development, and in the metastasis of tumours and inflammation.16–19

The mechanism of action of HA in the joint

The complete mechanism of HA in the joint is not fully understood, but a wide range of actions in the joint is recognized. It is known that the HA injected into the joint lasts a few hours or even a few days, being eliminated by the liver. In contrast, its effects can last for months. Its anti-inflammatory, analgesic, and chondroprotective action is related to the modulation of the intra- and extracellular inflammation cascade.20,21

The osteoarthritic environment contains a series of cytokines (IL-6, IL-8, IL-B1), metalloproteinases, nitric oxide, arachidonic acid, and other
proteins that act in the inflammatory cascade of OA. Exogenous HA has an inhibitory effect on this cascade, modulating the harmful effect of these substances on the cartilage.22,23

HA can bind to specific proteins called hyaladherin.24 Some of these are membrane proteins, such as CD44 (Cluster of Differentiation 44), acting as a modulator of the immune system by inhibiting the interleukins IL-1β and IL-6 and the expression of matrix metalloproteinase, reducing the PGE2 synthesis, contributing to the chondroprotection and proteoglycan/glycosaminoglycan synthesis, and having anti-inflammatory and subchondral effects. The release of cytokines also interferes with the regular cycle of the OA and, for all these reasons, HA is considered a disease-modifying drug.25,26

HA also reduces the activity of macrophages and the production and migration of polymorphonuclear leukocytes that are important for tissue repair and chronic inflammation, playing an immunomodulatory role in the genesis of cartilage catabolism.27

The IA HA therapy acts through a series of pathways, including the suppression (down-regulation) of pro-inflammatory cytokines via inhibition of cell surface receptors, such as the CD44 determinant, toll-like receptors 2 and 4, and layilin. This effect appears to be dependent on the HA molecular weight.28

Some in vitro studies demonstrate that HA of high molecular weight can down-regulate the gene expression of aggrecanase-2, TNF-a, IL-8, and nitric oxide synthase in the synoviocyte culture of patients with early-stage OA.29 The down-regulation of these inflammatory mediators suggests that HA of high molecular weight may have an anti-inflammatory and analgesic effect by inhibiting the leukocyte migration, free radical inactivation, and chemotaxis.30–32

The presumed HA disease-modifying activity may include effects on cartilage degradation. Indeed, exogenous HA can enhance chondrocyte synthesis of endogenous HA and proteoglycans, prevent cartilage degradation and promote its regeneration, and inhibit cellular inflammatory processes.33

Thus, HA therapy would also be effective in the treatment of post-traumatic, degenerative joint diseases, post-arthroscopy, post-surgical recovery, wound healing, and after prolonged immobilization.14,34–37

The term ‘viscoinduction’ was created to describe the phenomenon of the clinical benefits of HA.38 Viscoinduction ensures that clinical efficacy is maintained for several months, despite the half-life of IA HA being only a few days, which suggests that exogenous HA induces endogenous HA synthesis, possibly stimulating the regenerative process in the joint. Some in vitro studies indicate that synoviocytes from osteoarthritic joints resume the HA production after exposure to exogenous HA, restoring the viscoelastic properties of the synovial fluid – damping, lubrication, elasticity –, which change with the OA evolution.39

HA agents are generally administered as a weekly injection over 1–5 weeks and, although they have a slower onset of action compared with the steroid treatment, the pain relief obtained usually lasts longer – for up to several months, and without the harmful risks of steroids. In the literature, we find a long discussion about the tolerability and safety of using HA in the treatment of osteoarthritis.40

There are several presentations of HA marketed worldwide (80 or more), with different characteristics: origin (animal or biofermentation); molecular weight (from 500 to 9000 kDa); molecular structure (linear, cross-linked, and a mixture of both); concentration (from 0.8 to 30 mg/ml); volume per ampoule (from 0.5 to 6.0 ml); and application regime (from one to five applications). Some presentations include additives, such as mannitol or sorbitol. This great variability of products makes it difficult to establish a relevant clinical difference between them, especially concerning the molecular weight and application regime. In this regard, in a comparative study with more than 400 patients, Berenbaum et al.41 demonstrate better results on the Western Ontario and McMaster Universities (WOMAC) and visual analogue scales after a six-month follow-up with an intermediate molecular weight HA than with a low molecular weight HA.

In a review of 64 articles, Altman et al.42 demonstrate that HA differs greatly in the property and intrinsic characteristic of each product. However, this review shows significantly better results in terms of safety and efficacy when products with a molecular weight above 3000 kDa are used. This fact can help the clinician in choosing the HA among the available products.
Table 1. Chondropathy and hyaluronic acid in the medical literature.

| Study                                      | N     | Type              | Follow-up | Findings                                                                 |
|--------------------------------------------|-------|-------------------|-----------|--------------------------------------------------------------------------|
| Hempfling44                                 | 80    | Prospective       | 24 months | HA + debridement = debridement, except 100 m walk                       |
| Magarelli et al.45                         | –     | Prospective       | 12 months | MRI is a useful tool to evaluate chondral alterations after HA injections. MRI represents a useful tool to evaluate the grade of chondromalacia patellae and also to follow the cartilage modification induced by HA therapy |
| Jazrawi and Rosen46                        | –     | Meta-analysis     |           | Discusses the clinical improvement of patients with meniscal, chondral, and ACL injuries |
| Filardo et al.47                           | 192   | Blind, prospective | 12 months | HA = PRP in KOOS, IKDC, and VAS scores                                  |
| Shah et al.48                              | –     | Prospective       | 12 months | T1 rho MRI evaluated proteoglycans × WOMAC, VAS                         |
| Tamburrino and Castellacci49               | 40    | Prospective       | 6 months  | Improvement in KOOS AND VAS                                             |
| Hart et al.50                              | 86    | Prospective       | 6 months  | Improvement in KOOS                                                    |
| Di Martino et al.51                        | 189   | Blind, prospective | 64 months | HA = PRP in KOOS, IKDC, and VAS scores                                  |
| Astur et al.52                             | 63    | Prospective       | 6 months  | HA + better physiotherapy                                               |
| Zhang et al.53                             | 88    | Prospective       | 12 months | Better WOMAC and Lequesne                                              |

ACL, anterior cruciate ligament; HA, hyaluronic acid; IKDC, International Knee Documentation Committee; PRP, Platelet-rich plasma; KOOS, Knee injury and Osteoarthritis Outcome Score; MRI, magnetic resonance imaging; VAS, visual analogue scale; WOMAC, Western Ontario and McMaster Universities.

In their review article, Johal et al.43 suggest that HA with high molecular weight or cross-linking HA are safe options for pain reduction in younger patients with knee osteoarthritis.

**HA and patellar chondropathy**

Although the topic is important, there are still few articles published. Some authors have sought to demonstrate scientific evidence on the use of HA in patellar chondropathy to demonstrate the clinical improvement achieved and understand the mechanism of the HA action. See Table 1.

To understand the mechanism of HA action, Shah et al.48 demonstrated in a study with 10 patients a reduction in mean values of T1 rho magnetic resonance imaging (MRI) in six of nine patellar segments in six weeks, suggesting an increase in the content of proteoglycans. Simultaneously, there was an improvement on the Western Ontario and McMaster Universities (WOMAC) visual analogue scale (VAS), and International Knee Documentation Committee (IKDC) scores, suggesting that HA could alter the natural course of the disease. T1 rho is an MRI modality that provides detailed images of the cartilage quality, allowing the quantification of early physiological changes in the cartilage considering the proteoglycan content.

Hempfling44 demonstrated benefits with the use of HA after arthroscopic debridement when compared with debridement alone in a knee with chondral injuries. Magarelli et al.45 observed patellar cartilage changes on MRI in patients with chondropathy after treatment with HA. According to Jazrawi and Rosen,46 some clinical trials demonstrate the benefit of IA HA injections in younger patients with acute knee injuries, including symptomatic meniscal injuries and isolated anterior cruciate ligament injury with chondral injury.
The use of HA showed promising results in patients undergoing knee arthroscopy, and IA HA also showed direct antinociceptive effects that may contribute to its benefit in patients with patellofemoral pain. In a prospective, randomized, double-blind clinical study, Hart et al. found no difference between two groups of patients submitted to a single injection of HA (Synvisc One) compared with the placebo group after 6 months. The parameters analysed were the Kujala scale and VAS, Tegner activity rating, Knee injury and Osteoarthritis Outcome Score (KOOS), normalized maximal voluntary knee extension torque, and central activation ratio, as measured at baseline and at 1, 3, and 6 months post-randomization. Tamburrino and Castellacci published an article with good results with two applications of a hydrogel based on a HA derivative (HYADD4-g) in 40 professional football players from the Italian League evaluated according to KOOS and VAS at 1, 3, and 6 months of follow-up. Lohse et al. published a case series involving children and adolescents from 10 to 16 years old with patellofemoral chondropathy. Thirteen of the 16 patients had excellent or good results and returned to their sports activities when submitted to one or three injections of IA HA. Although it is a case series, this study indicates the possibility of using HA safely in this group age. In a comparative, prospective study involving 189 patients with a mean age of 54 years and with a painful and degenerative condition in the knee, including chondropathy, Filardo et al. found no difference between the groups treated with HA and with platelet-rich plasma over 12 months in the IKDC, Tegner, KOOS, and VAS scores. Patients were subsequently followed up at 64 months and the results remained unchanged. Astur et al. showed that 70 patients undergoing treatment for chondral patellar injuries of grades II or III with the use of exogenous IA HA associated with physiotherapy rehabilitation had better results for pain and knee function when compared with patients undergoing only physiotherapy treatment 3 and 6 months after diagnosis.

In a prospective study with 88 patients and a 52-week follow-up, Zhang et al. showed that patients from a patellofemoral arthritis group and an early chondropathy group had significantly decreased WOMAC scores and Lequesne scores at four or 12 weeks after the injections. These scores at 26 and 52 weeks after the injections were significantly higher in the patellofemoral arthritis group than in the early chondropathy group.

The control of joint pain in patellar chondropathy involves understanding the complex mechanism of inflammation and tissue damage and repairs modulated by various inflammatory mediators, such as cytokines, tumour necrosis factor, prostaglandin-E, bradykinin, and substance P, as well as the roles played by the immune system, collagen production, and cell apoptosis. It is hard to believe that a single molecule or drug can make it alone, therefore, so far, the multimodal treatment of pain seems to be the answer.

**Conclusion**

The search for disease-modifying drugs for the treatment of OA has become a priority in the field of orthopaedics. HA has been shown to be safe and effective in the treatment of pain related to OA in the knee and other joints, confirming that HA may have some disease-modifying property.

**Conflict of interest statement**

The authors declare that there is no conflict of interest.

**Funding**

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**ORCID iD**

Sergio Ricardo da Costa https://orcid.org/0000-0001-7224-0319

**References**

1. Barber Foss KD, Myer GD, Chen SS, et al. Expected prevalence from the differential diagnosis of anterior knee pain in adolescent female athletes during preparticipation screening. *J Athl Train* 2012; 47: 519–524.

2. Roush JR and Curtis Bay R. Prevalence of anterior knee pain in 18-35 year-old females. *Int J Sports Phys Ther* 2012; 7: 396–401.

3. Glaviano NR, Kew M, Hart JM, et al. Demographic and epidemiological trends in patellofemoral pain. *Int J Sports Phys Ther* 2015; 10: 281–290.
4. Budinger K. Uber ablosung von gelenktulen und verwandte prozesse. *Dtsch Z Chir* 1906; 84: 311–365.
5. Thomas MJ, Wood L, Selfe J, et al. Anterior knee pain in younger adults as a precursor to subsequent patellofemoral osteoarthritis: a systematic review. *BMC Musculoskelet Disord* 2010; 11: 201.
6. Besier TF, Draper C, Pal S, et al. Imaging and musculoskeletal modeling to investigate the mechanical etiology of patellofemoral pain. In: Sanchis-Alfonso V (ed.) *Anterior knee pain and patellar instability*. London: Springer-Verlag, 2011, pp. 269–286.
7. Dye SF, Vaupel GL and Dye CC. Conscious neurosensory mapping of the internal structures of the human knee without intraarticular anesthesia. *Am J Sports Med* 1998; 26: 773–777.
8. Sanchis-Alfonso V, Roselló-Sastre E and Revert F. Neural growth factor expression in the lateral retinaculum in painful patellofemoral malalignment. *Acta Orthop Scand* 2001; 72: 146–149.
9. Dye SF. The pathophysiology of patellofemoral pain: a tissue homeostasis perspective. *Clin Orthop Relat Res* 2005; 436: 100–110.
10. Luke AC, Stehling C, Stahl R, et al. High-field magnetic resonance imaging assessment of articular cartilage before and after marathon running: does long-distance running lead to cartilage damage? *Am J Sports Med* 2010; 38: 2273–2280.
11. Pappas GP, Vogelsong MA, Staroswiecki E, et al. Magnetic resonance imaging of asymptomatic knees in collegiate basketball players: the effect of one season of play. *Clin Orthop Relat Res* 2016; 26: 483–489.
12. Balazs EA. The physical properties of synovial fluid and the special role of hyaluronic acid. In: Helfet AJ (ed.) *Disorders of the knee*. Philadelphia: Lippincott, 1974, pp. 61–74.
13. Uthman I, Raynauld JP and Haraaoui B. Intra-articular therapy in osteoarthritis. *Postgrad Med J* 2003; 79: 449–453.
14. Goldberg VM and Buckwalter JA. Hyaluronans in the treatment of osteoarthritis of the knee: evidence for disease-modifying activity. *Osteoarthritis Cartilage* 2005; 13: 216–224.
15. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. *Osteoarthritis Cartilage* 2019; 27: 1578–1589.
16. Toole BP, Wight TN and Tammi MI. Hyaluronan-cell interactions in cancer and vascular disease. *J Biol Chem* 2002; 277: 4593–4596.
17. Turley EA, Noble PW and Bourguignon LY. Signaling properties of hyaluronan receptors. *J Biol Chem* 2002; 277: 4589–4592.
18. Hascall VC, Majors AK, De La Motte CA, et al. Intracellular hyaluronan: a new frontier for inflammation? *Biochim Biophys Acta* 2004; 1673: 3–12.
19. Balazs EA and Denlinger JL. Clinical uses of hyaluronan. In: Evered D and Whelan J (eds) *The biology of hyaluronan*. Sussex: Wiley-Interscience Publication, 2007.
20. Moreland LW. Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action. *Arthritis Rheum* 2003; 5: 54–67.
21. Wang A, de la Motte C, Lauer M, et al. Hyaluronan matrices in pathobiological processes. *FEBS J* 2011; 278: 1412–1418.
22. Stitik TP and Levy JA. Viscosupplementation (biosupplementation) for osteoarthritis. *Am J Phys Med Rehabil* 2006; 85: S32–S50.
23. Wang CT, Lin J, Chang CJ, et al. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. A meta-analysis of randomized controlled trials. *J Bone Joint Surg Am* 2004; 86: 538–545.
24. Toole BP. Hyaluronan and its binding proteins, the hyaladherins. *Curr Opin Cell Biol* 1990; 2: 839–844.
25. Altman RD, Manjoo A, Fierlinger A, et al. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review. *BMC Musculoskelet Disord* 2015; 16: 321.
26. Miyazaki T, Sakamoto T, Aoki N, et al. Does hyaluronic acid injection prevent the progression of knee osteoarthritis? *Osteoarthritis Cartilage* 2020; 28: S500.
27. Corrado EM, Peluso GF, Gigliotti S, et al. The effects of intra-articular administration of hyaluronic acid on osteo-arthritis of the knee: a clinical study with immunological and biochemical evaluations. *Eur J Rheumatol Inflamm* 1995; 15: 47–56.
28. Altman R, Bedi A, Manjoo A, et al. Anti-inflammatory effects of intra-articular hyaluronic acid: a systematic review. *Carrilage* 2019; 10: 43–52.
29. Wang CT, Lin YT, Chiang BL, et al. High molecular weight hyaluronic acid down-regulates...
the gene expression of osteoarthritis-associated cytokines and enzymes in fibroblast-like synoviocytes from patients with early osteoarthritis. *Osteoarthritis Cartilage* 2006; 14: 1237–1247.

30. Selyanin MA, Boykov PY, Khabarov VN, *et al.* Medical applications of hyaluronan. In: Khabarov VN, Boykov PY, Selyanin MA, *et al.* (eds) *Hyaluronic acid.* John Wiley & Sons Ltd, 2015, pp.143–192.

31. Sato H, Takahashi T, Ide H, *et al.* Antioxidant activity of synovial fluid, hyaluronic acid, and two subcomponents of hyaluronic acid. Synovial fluid scavenging effect is enhanced in rheumatoid arthritis patients. *Arthritis Rheum* 1988; 31: 63–71.

32. Presti D and Scott JE. Hyaluronan-mediated protective effect against cell damage caused by enzymatically produced hydroxyl (OH.) radicals is dependent on hyaluronan molecular mass. *Cell Biochem Funct* 1994; 12: 281–288.

33. Migliore A and Procopio S. Effectiveness and utility of hyaluronic acid in osteoarthritis. *Clin Cases Miner Bone Metab* 2015; 12: 31–33.

34. Di Marco C and Letizia GA. Hyaluronic acid in the treatment of pain due to knee joint immobilization. *Clin Drug Invest* 1995; 10: 191–197.

35. Zattoni G, Cabrioli A, Brunelli G, *et al.* Efficacy and tolerability of hyaluronic acid in acute knee injury: a controlled study. *Eur J Rheumatol Inflamm* 1995; 15: 63–69.

36. Punzi L. The complexity of the mechanisms of action of hyaluronan in joint diseases. *Clin Exp Rheumatol* 2001; 19: 242–246.

37. Wang CW, Gao LH, Jin XY, *et al.* The observation of the effectiveness of sodium hyaluronate injection after surgery. *Chin J Reparative Reconstr Surg* 2002; 16: 1–8.

38. Gigante A and Callegari L. The role of intra-articular hyaluronan (Sinovial) in the treatment of osteoarthritis. *Rheumatol Int* 2010; 31: 427–444.

39. Bongkotphet K, Tassanawipas W, Krittiyanunt S, *et al.* Comparative efficacy of low-and high-molecular weight intra-articular hyaluronic acids in patients with knee osteoarthritis. *J Health Res* 2009; 23: 87–91.

40. Cooper C, Rannou F, Richette P, *et al.* Use of intraarticular hyaluronic acid in the management of knee osteoarthritis in clinical practice. *Arthritis Care Res (Hoboken)* 2017; 69: 1287–1296.

41. Berenbaum F, Grifka J, Cazzaniga S, *et al.* A randomised, double-blind, controlled trial comparing two intra-articular hyaluronic acid preparations differing by their molecular weight in symptomatic knee osteoarthritis. *Ann Rheum Dis* 2012; 71: 1454–1460.

42. Altman RD, Bedi A, Karlsson J, *et al.* Product differences in intra-articular hyaluronic acids for osteoarthritis of the knee. *Am J Sports Med* 2016; 44: 2158–2165.

43. Johal H, Devji T, Schemitsch EH, *et al.* Viscosupplementation in knee osteoarthritis: evidence revisited. *JBJS Rev* 2016; 4: e11–e111.

44. Hampfling H. Intra-articular hyaluronic acid after knee arthroscopy: a two-year study. *Knee Surg Sports Traumatol Arthrosoc* 2007; 15: 537–546.

45. Magarelli N, Palmieri D, Ottaviano L, *et al.* Evaluation of magnetic resonance signal modification induced by hyaluronic acid therapy in chondromalacia patellae: a preliminary study. *J Biol Regul Homeost Agents* 2008; 22: 247–252.

46. Jazrawi LM and Rosen J. Intra-articular hyaluronic acid: potential treatment of younger patients with knee injury and/or post-traumatic arthritis. *Phys Sportsmed* 2011; 39: 107–113.

47. Filardo G, Di Matteo B, Di Martino A, *et al.* Platelet-rich plasma intra-articular knee injections show no superiority versus viscosupplementation: a randomized controlled trial. *Am J Sports Med* 2015; 43: 1575–1582.

48. Shah RP, Stambough JB, Fenty M, *et al.* T1rho magnetic resonance imaging at 3T detects knee cartilage changes after viscosupplementation. *Orthopedics* 2015; 38: e604–e610.

49. Tamburrino P and Castellacci E. Intra-articular injections of HYADD4-G in male professional soccer players with traumatic or degenerative knee chondromalacia. A pilot, prospective study. *J Sports Med Phys Fitness* 2016; 56: 1534–1539.

50. Hart JM, Kuenze C, Norte G, *et al.* Prospective, randomized, double-blind evaluation of the efficacy of a single-dose hyaluronic acid for the treatment of patellofemoral chondromalacia. *Orthop J Sports Med* 2019; 7: 2325967119854192.

51. Di Martino A, Di Matteo B, Papio T, *et al.* Platelet-rich plasma versus hyaluronic acid for the treatment of patellofemoral chondromalacia- a six-month randomized controlled trial. *Orthop J Sports Med* 2019; 7: 2325967119854192.

52. Astur DC, Angelini FB, Santos MA, *et al.* Use of exogenous hyaluronic acid for the treatment of patellar chondropathy- a six-month randomized controlled trial. *Rev Bras Ortop (Sao Paulo)* 2019; 54: 549–555.
53. Zhang S, Jia M, Luo Y, et al. [Hyaluronate acid for treatment of chondromalacia patellae: a 52-week follow-up study]. Nan Fang Yi Ke Da Xue Xue Bao 2019; 39: 791–796.

54. Lohse A, Gizard A, Balblanc JC, et al. Hyaluronic acid intra-articular injections for treating idiopathic patello-femoral chondropathy in adolescents. Adv Ortho Sports Med 2020; AOASM-117.

55. Niki Y. In knee degenerative disease, intra-articular injections of platelet-rich plasma and hyaluronic acid did not differ for clinical scores or duration of effect at a mean of 64.3 months. J Bone Joint Surg Am 2019; 101: 1515.

56. Näslund J. In search of the etiology of anterior knee pain. In: Sanchis-Alfonso V (ed.) Anterior knee pain and patellar instability. London: Springer-Verlag, 2011, pp.21–32.